| 摘要 |
<p>Disclosed herein are benzylamide compounds of formula (I), wherein the substituents are as defined in the specification. Also disclosed are pharmaceutical compositions comprising a compound of formula (I) for the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated selected from impaired visual acuity, diabetic retinopathy, diabetic macular oedema, hereditary angioedema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, cardiopulmonary bypass surgery and bleeding from post-operative surgery. Examples of a compound of formula (I) are: (S)-N-(4-Aminomethyl-benzyl)-2-[(R)-3-(4-ethoxy-phenyl)-2-propionylaminopropionylamino]-3-phenyl-propionamide (R)-N-[(S)-1-(4-Aminomethyl-benzylcarbamoyl)-2-phenyl-ethyl]-3-(4-ethoxy-phenyl)-2-methanesulfonylamino-propionamide N-[(R)-1-[(S)-1-(4-Aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyll-2-(4-ethoxyphenyl)-ethyl]-benzamide { (R)-1-[(S)-1-(4-Aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyll-2-cyclohexyl-ethylamino} -acetic acid</p> |
